Key result
Cyclophilin A and CD147 significantly contribute to renal inflammation, acute kidney injury, renal fibrosis, and renal cell carcinoma, presenting potential implications for treatment.
This review highlights the significant contributions of Cyclophilin A and CD147 to various kidney diseases and their potential as therapeutic targets.
Warrants no change in kidney disease management; leaves open validation of CD147/cyclophilin A targeting in prospective trials.
CD147 is a widely expressed integral plasma membrane glycoprotein and has been involved in a variety of physiological and pathological activities in combination with different partners, including cyclophilins, caveolin-1, monocarboxylate transporters, and integrins. Recent data demonstrate that both CyPA and CD147 significantly contribute to renal inflammation, acute kidney injury, renal fibrosis, and renal cell carcinoma. Here we review the current understanding of cyclophilin A and CD147 expression and functions in kidney diseases and potential implications for treatment of kidney diseases.
No takes yet. Share an insight, caveat, or question.
Qu et al. (2014) conducted a review in Kidney diseases. CD147 and Cyclophilin A was evaluated. Cyclophilin A and CD147 significantly contribute to renal inflammation, acute kidney injury, renal fibrosis, and renal cell carcinoma, presenting potential implications for treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: